

# Voretigene neparvovec for treating inherited retinal dystrophies caused by RPE65 gene mutations

Information for the public

Published: 9 October 2019

[www.nice.org.uk](http://www.nice.org.uk)

Voretigene neparvovec (Luxturna) is available on the NHS as a possible treatment for RPE65-mediated inherited retinal dystrophies. It is for use in people with vision loss caused by inherited retinal dystrophy from confirmed biallelic RPE65 mutations and who have enough viable retinal cells.

## Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

## Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

## Information and support

These organisations can give you advice and support:

- [Fight for Sight](#), 0207 264 3900
- [Retina UK](#), 01280 821334

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-3554-3